The hemostatic system and coronary heart disease.

[1]  D. Steinberg,et al.  Role of oxidized low density lipoprotein in atherogenesis. , 1991, The Journal of clinical investigation.

[2]  S. Schwartz.  Serum-derived growth factor is thrombin? , 1993, The Journal of clinical investigation.

[3]  M. Davies,et al.  Atherosclerosis: what is it and why does it occur? , 1993, British heart journal.

[4]  I. Juhan-vague,et al.  Phosphatidylinositol turnover during stimulation of plasminogen activator inhibitor-1 secretion induced by oxidized low density lipoproteins in human endothelial cells. , 1993, Journal of lipid research.

[5]  M. Roncaglioni,et al.  Von Willebrand Factor, Plasminogen Activator Inhibitor-1 and C-Reactive Protein Are Markers of Thrombolytic Efficacy in Acute Myocardial Infarction , 1992, Thrombosis and Haemostasis.

[6]  J. Saffitz,et al.  Induction of Endothelial Cell Expression of the Plasminogen Activator Inhibitor Type 1 Gene by Thrombosis In Vivo , 1992, Circulation.

[7]  B. Sobel,et al.  Augmented arterial wall expression of type-1 plasminogen activator inhibitor induced by thrombosis. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[8]  S. Rapaport,et al.  Initiation and regulation of tissue factor-dependent blood coagulation. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[9]  P. Marckmann,et al.  The variability of and associations between measures of blood coagulation, fibrinolysis and blood lipids. , 1992, Atherosclerosis.

[10]  W. Halbmayer,et al.  The Prevalence of Factor XII Deficiency in 103 Orally Anticoagulated Outpatients Suffering from Recurrent Venous and/or Arterial Thromboembolism , 1992, Thrombosis and Haemostasis.

[11]  A. Banerjee,et al.  A Six Year Prospective Study of Fibrinogen and Other Risk Factors Associated with Mortality in Stable Claudicants , 1992, Thrombosis and Haemostasis.

[12]  M. Blombäck,et al.  Fibrin Gel Network Characteristics and Coronary Heart Disease: Relations to Plasma Fibrinogen Concentration, Acute Phase Protein, Serum Lipoproteins and Coronary Atherosclerosis , 1992, Thrombosis and Haemostasis.

[13]  S. Dawson,et al.  The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. , 1992, Atherosclerosis.

[14]  S. Moestrup,et al.  Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. , 1992, The Journal of biological chemistry.

[15]  B. Sobel,et al.  Stimulation by Proinsulin of Expression of Plasminogen Activator Inhibitor Type-I in Endothelial Cells , 1992, Diabetes.

[16]  B. Sobel,et al.  Post-transcriptional regulation of expression of plasminogen activator inhibitor type 1 mRNA by insulin and insulin-like growth factor 1. , 1992, The Journal of biological chemistry.

[17]  R. Miller,et al.  Correlation of factor VII activity and antigen with cholesterol and triglycerides in healthy young adults. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[18]  K. Huber,et al.  A Decrease in Plasminogen Activator Inhibitor-1 Activity after Successful Percutaneous Transluminal Coronary Angioplasty Is Associated with a Significantly Reduced Risk for Coronary Restenosis , 1992, Thrombosis and Haemostasis.

[19]  M. Blombäck,et al.  von Willebrand Factor in Plasma and Urine of Men with Premature Coronary Artery Disease , 1992, Thrombosis and Haemostasis.

[20]  H. Yki-Järvinen,et al.  No Evidence for Short-Term Regulation of Plasminogen Activator Inhibitor Activity by Insulin in Man , 1992, Thrombosis and Haemostasis.

[21]  B. Sobel,et al.  Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: Implications for vascular disease in hyperinsulinemic states , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[22]  P. Bjerle,et al.  Increased plasminogen activator inhibitor and tissue plasminogen activator levels in subjects with electrocardiographic abnormality indicative of ischaemic heart disease: a cross-sectional study in Norsjö, Sweden. , 1992, European heart journal.

[23]  P. Sever,et al.  Haemorheological changes in the very short term after abstention from tobacco by cigarette smokers , 1991, British journal of haematology.

[24]  A. Hamsten,et al.  Impaired fibrinolysis and risk of thromboembolism. , 1991, Progress in cardiovascular diseases.

[25]  M. Alessi,et al.  Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[26]  J. Jansson,et al.  von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. , 1991, British heart journal.

[27]  J. Cooper,et al.  Antithrombin III and arterial disease , 1991, The Lancet.

[28]  Toshikazu Suzuki,et al.  Elevation of factor VII activity and mass in coronary artery disease of varying severity , 1991, Clinical cardiology.

[29]  J. Shafer,et al.  A kinetic model for the alpha-thrombin-catalyzed conversion of plasma levels of fibrinogen to fibrin in the presence of antithrombin III. , 1991, The Journal of biological chemistry.

[30]  D. Rader,et al.  Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. , 1991, Blood.

[31]  R. Stout,et al.  Seasonal variations in fibrinogen concentrations among elderly people , 1991, The Lancet.

[32]  C. Reilly,et al.  Plasminogen Activator Inhibitor‐1 Suppresses Endogenous Fibrinolysis in a Canine Model of Pulmonary Embolism , 1991, Circulation.

[33]  W. Roberts,et al.  Effectiveness of Recombinant Desulphatohirudin in Reducing Restenosis After Balloon Angioplasty of Atherosclerotic Femoral Arteries in Rabbits , 1991, Circulation.

[34]  S. Humphries,et al.  Variation in the Promoter Region of the β Fibrinogen Gene Is Associated with Plasma Fibrinogen Levels in Smokers and Non-Smokers , 1991, Thrombosis and Haemostasis.

[35]  T. Meade,et al.  A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[36]  D. Fischman,et al.  Evidence for Reduced Fibrinolytic Activity in Unstable Angina at Rest: Clinical, Biochemical, and Angiographic Correlates , 1991, Circulation.

[37]  C. Forbes,et al.  Relationships of Plasma Viscosity, Coagulation and Fibrinolysis to Coronary Risk Factors and Angina , 1991, Thrombosis and Haemostasis.

[38]  J. P. Wade,et al.  Gold-induced neuroencephalopathy responding to dimercaprol , 1991, The Lancet.

[39]  J. Jansson,et al.  Hypofibrinolysis in patients with hypertension and elevated cholesterol , 1991, Journal of internal medicine.

[40]  R. Califf,et al.  Correlation between Baseline Plasminogen Activator Inhibitor Levels and Clinical Outcome during Therapy with Tissue Plasminogen Activator for Acute Myocardial Infarction , 1991, Thrombosis and Haemostasis.

[41]  T. Kristensen,et al.  Plasma fibrinogen and ischemic heart disease risk factors. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[42]  P C Elwood,et al.  Fibrinogen, Viscosity, and White Blood Cell Count Are Major Risk Factors for Ischemic Heart Disease: The Caerphilly and Speedwell Collaborative Heart Disease Studies , 1991, Circulation.

[43]  B. Lämmle,et al.  Thromboembolism and Bleeding Tendency in Congenital Factor XII DeficienCy - A Study on 74 Subjects from 14 Swiss Families , 1991, Thrombosis and Haemostasis.

[44]  J. Cooper,et al.  Plasma factor VII is activated by postprandial triglyceridaemia, irrespective of dietary fat composition. , 1991, Atherosclerosis.

[45]  B. Sobel,et al.  Mechanisms contributing to increased synthesis of plasminogen activator inhibitor type 1 in endothelial cells by constituents of platelets and their implications for thrombolysis. , 1991, Circulation.

[46]  U. Smith,et al.  Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors , 1991, Journal of internal medicine.

[47]  J. Jansson,et al.  Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. , 1991, European heart journal.

[48]  A. Henney,et al.  Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[49]  A. Hamsten.  9 Hypertriglyceridaemia, triglyceride-rich lipoproteins and coronary heart disease , 1990 .

[50]  M. Roncaglioni,et al.  Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarction. , 1990, Journal of the American College of Cardiology.

[51]  E. Raftery,et al.  Fibrinogen, factor VII clotting activity and coronary artery disease severity. , 1990, Atherosclerosis.

[52]  B. Sobel,et al.  Induction of Synthesis of Plasminogen Activator Inhibitor Type-1 byTissue-Type Plasminogen Activator in Human Hepatic and Endothelial Cells , 1990, Thrombosis and Haemostasis.

[53]  W. Kisiel,et al.  Formation of tissue factor activity following incubation of recombinant human tissue factor apoprotein with plasma lipoproteins. , 1990, Thrombosis research.

[54]  J. Felber,et al.  Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man. , 1990, Clinical science.

[55]  J. Agmon,et al.  Plasma viscosity, fibrinogen and haematocrit in the course of unstable angina. , 1990, European heart journal.

[56]  P. Durrington,et al.  Lipoprotein (a): structure, properties and possible involvement in thrombogenesis and atherogenesis. , 1990, Atherosclerosis.

[57]  A. Hamsten,et al.  Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. , 1990, Arteriosclerosis.

[58]  J. H. van Bockel,et al.  Hereditary Protein S Deficiency in Young Adults with Arterial Occlusive Disease , 1990, Thrombosis and Haemostasis.

[59]  U. Smith,et al.  Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. , 1990, Metabolism: clinical and experimental.

[60]  S. Suzuki,et al.  Clinical significance of plasminogen activator inhibitor activity in patients with exercise-induced ischemia. , 1990, American heart journal.

[61]  B. Sobel,et al.  Induction of plasminogen activator inhibitor by products released from platelets. , 1990, Circulation.

[62]  A. Lusis,et al.  Dietary regulation of fibrinolytic factors. , 1990, Atherosclerosis.

[63]  W. Chandler,et al.  Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (t-PA) and t-PA/PAI-1 complex in plasma. , 1990, Blood.

[64]  J. Buring,et al.  Antiplatelet therapy to prevent coronary artery bypass graft occlusion. , 1990, Circulation.

[65]  H. ten Cate,et al.  Factor IX is activated in vivo by the tissue factor mechanism. , 1990, Blood.

[66]  A. Hofman,et al.  Haemophilia protects against ischaemic heart disease: a study of risk factors , 1990, British journal of haematology.

[67]  K. Pasi,et al.  Qualitative and quantitative abnormalities of von Willebrand antigen in patients with diabetes mellitus. , 1990, Thrombosis research.

[68]  K. Marotti,et al.  Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene , 1990, Nature.

[69]  A. Hamsten,et al.  The Fibrinolytic Enzyme System and Its Role in the Etiology of Thromboembolic Disease , 1990, Seminars in thrombosis and hemostasis.

[70]  J. Freyssinet,et al.  Screening of protein S deficiency using a functional assay in patients with venous and arterial thrombosis. , 1990, Thrombosis research.

[71]  J. Jespersen,et al.  A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction. , 1990, European heart journal.

[72]  C. Hales,et al.  RADIOIMMUNOASSAY MAY OVERESTIMATE INSULIN IN NON‐INSULIN‐DEPENDENT DIABETICS , 1990, Clinical endocrinology.

[73]  H. Arnesen,et al.  Effects of Gemfibrozil on Lipids and Haemostasis after Myocardial Infarction , 1990, Thrombosis and Haemostasis.

[74]  U. Smith,et al.  Elevated fibrinogen and plasminogen activator inhibitor (PAI‐1) in hypertension are related to metabolic risk factors for cardiovascular disease , 1990, Journal of internal medicine.

[75]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias , 1990, The Lancet.

[76]  L. Wilhelmsen,et al.  Social influences and cardiovascular risk factors as determinants of plasma fibrinogen concentration in a general population sample of middle aged men. , 1990, BMJ.

[77]  J. Loscalzo,et al.  Lipoprotein(a), fibrin binding, and plasminogen activation. , 1990, Arteriosclerosis.

[78]  E. B. Smith,et al.  Fate of fibrinogen in human arterial intima. , 1990, Arteriosclerosis.

[79]  C. Prentice,et al.  Premature Arterial Disease Associated with Familial Antithrombin III Deficiency , 1990, Thrombosis and Haemostasis.

[80]  M. Esnouf,et al.  The prothrombin activation peptide regulates synthesis of the vitamin K-dependent proteins in the rabbit. , 1990, Thrombosis research.

[81]  D. Graham,et al.  The effects of thrombin on bovine aortic endothelial and smooth muscle cells. , 1990, Journal of vascular surgery.

[82]  H. Portugal,et al.  Effect of low density lipoproteins on secretion of plasminogen activator inhibitor-1 (PAI-1) by human endothelial cells and hepatoma cells. , 1990 .

[83]  A. Meinders,et al.  Acute exogenous hyperinsulinaemia does not result in elevation of plasma plasminogen activator inhibitor-1 (PAI-1) in humans , 1990 .

[84]  E. Tremoli,et al.  Atherogenic lipoproteins and release of plasminogen activator inhibitor-1 (PAI-1) by endothelial cells , 1990 .

[85]  H. Tunstall-Pedoe,et al.  Plasma fibrinogen and coronary risk factors: The Scottish heart health study , 1990 .

[86]  C. Kluft,et al.  Alcohol and Fibrinolysis , 1990 .

[87]  A. Hamsten,et al.  Native fibrin gel networks and factors influencing their formation in health and disease. , 1990, Advances in experimental medicine and biology.

[88]  M. Mancini,et al.  Measuring plasma fibrinogen to predict stroke and myocardial infarction. , 1990, Arteriosclerosis.

[89]  H. Hod,et al.  Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction. , 1989, The American journal of cardiology.

[90]  R. Sacco,et al.  Free protein S deficiency: a possible association with cerebrovascular occlusion. , 1989, Stroke.

[91]  J. Cazenave,et al.  Arterial Thrombosis and Protein S Deficiency , 1989, Thrombosis and Haemostasis.

[92]  G. Hallmans,et al.  Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a), and established cardiovascular risk factors in a north Swedish population. , 1989, Atherosclerosis.

[93]  H. Prydz,et al.  Effect of alteration in triglyceride levels on factor VII-phospholipid complexes in plasma. , 1989, Arteriosclerosis.

[94]  B. Sobel.  Coronary thrombolysis and the new biology. , 1989, Journal of the American College of Cardiology.

[95]  W. Lawson,et al.  Elevation of factor VII activity and mass in young adults at risk of ischemic heart disease. , 1989, Journal of the American College of Cardiology.

[96]  P. Kierulf,et al.  DNA polymorphisms at fibrinogen loci and plasma fibrinogen concentration , 1989, Clinical genetics.

[97]  P. Rentrop,et al.  Impaired Fibrinolytic Capacity and Tissue Plasminogen Activator Release in Patients with Restenosis after Percutaneous Transluminal Coronary Angioplasty (PTCA) , 1989, Thrombosis and Haemostasis.

[98]  P. Bosma,et al.  Plasminogen Activator Inhibitor 1: Biosynthesis and mRNA Level Are Increased by Insulin in Cultured Human Hepatocytes , 1989, Thrombosis and Haemostasis.

[99]  U. Beisiegel,et al.  The LDL–receptor–related protein, LRP, is an apolipoprotein E-binding protein , 1989, Nature.

[100]  M. Richardson,et al.  Deendothelialization in vivo initiates a thrombogenic reaction at the rabbit aorta surface. Correlation of uptake of fibrinogen and antithrombin III with thrombin generation by the exposed subendothelium. , 1989, The American journal of pathology.

[101]  P. Vague,et al.  Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. , 1989, Metabolism: clinical and experimental.

[102]  M. Brown,et al.  Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[103]  P. Sandset,et al.  Factor VII and extrinsic pathway inhibitor in acute coronary disease , 1989, British journal of haematology.

[104]  J. Jansson,et al.  Impact of acute phase on concentrations of tissue plasminogen activator and plasminogen activator inhibitor in plasma after deep-vein thrombosis or open-heart surgery. , 1989, Clinical chemistry.

[105]  P. Vague,et al.  Increased Plasminogen Activator Inhibitor Activity in Non Insulin Dependent Diabetic Patients – Relationship with Plasma Insulin , 1989, Thrombosis and Haemostasis.

[106]  B. Sobel,et al.  Potential attenuation of fibrinolysis by growth factors released from platelets and their pharmacologic implications. , 1989, The American journal of cardiology.

[107]  J. Sasaki,et al.  Plasma fibrinogen levels as an independent indicator of severity of coronary atherosclerosis. , 1989, Atherosclerosis.

[108]  J. Breslow,et al.  Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis , 1989, Nature.

[109]  A. Scanu,et al.  A potential basis for the thrombotic risks associated with lipoprotein(a) , 1989, Nature.

[110]  K. Mann,et al.  Zymogen/enzyme discrimination using peptide chloromethyl ketones. , 1989, The Journal of biological chemistry.

[111]  B. Gordon,et al.  Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[112]  M. Esnouf,et al.  The activation of the contact phase of coagulation by physiologic surfaces in plasma: the effect of large negatively charged liposomal vesicles. , 1989, Blood.

[113]  J. Cruickshank,et al.  Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men. , 1989, Atherosclerosis.

[114]  Kathleen M. Smith,et al.  Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[115]  S. Pizzo,et al.  Further characterization of the cellular plasminogen binding site: evidence that plasminogen 2 and lipoprotein a compete for the same site. , 1989, Biochemistry.

[116]  S. Pizzo,et al.  Lipoprotein a inhibits streptokinase-mediated activation of human plasminogen. , 1989, Biochemistry.

[117]  A. Gallus,et al.  Acute phase reaction, fibrinogen level and thrombus size. , 1989, Thrombosis research.

[118]  P. Simioni,et al.  Severe Arterial Cerebral Thrombosis in a Patient with Protein S Deficiency (Moderately Reduced Total and Markedly Reduced Free Protein S): A Family Study , 1989, Thrombosis and Haemostasis.

[119]  D. Owens,et al.  INSULIN DEFICIENCY IN NON-INSULIN-DEPENDENT DIABETES , 1989, The Lancet.

[120]  M. Austin.  Plasma triglyceride as a risk factor for coronary heart disease. The epidemiologic evidence and beyond. , 1989, American journal of epidemiology.

[121]  J. Vandenbroucke,et al.  Mortality and causes of death in Dutch haemophiliacs, 1973–86 , 1989, British journal of haematology.

[122]  A. Bini.  Identification and distribution of fibrinogen, fibrin and fibrin (ogen) degradation products in atherosclerosis , 1989 .

[123]  C. Soria,et al.  Coagulation Factor VII and Plasma Triglycerides , 1989 .

[124]  R. Stenling,et al.  Reduction of Elevated Plasminogen Activator Inhibitor Levels During Modest Weight Loss , 1989 .

[125]  A. Hassett,et al.  Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease. , 1989, The Journal of laboratory and clinical medicine.

[126]  G. Dahlén,et al.  Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. , 1989, European heart journal.

[127]  W. Chandler,et al.  Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). , 1989, Circulation.

[128]  I. Holme,et al.  Increased fibrinolytic potential after diet intervention in healthy coronary high-risk individuals. , 2009, Acta medica Scandinavica.

[129]  T. Kooistra,et al.  Insulin Stimulates the Synthesis of Plasminogen Activator Inhibitor 1 by the Human Hepatocellular Cell Line Hep G2 , 1988, Thrombosis and Haemostasis.

[130]  K. Huber,et al.  Circadian Fluctuations of Plasminogen Activator Inhibitor and Tissue Plasminogen Activator Levels in Plasma of Patients with Unstable Coronary Artery Disease and Acute Myocardial Infarction , 1988, Thrombosis and Haemostasis.

[131]  G. Reaven.  Role of Insulin Resistance in Human Disease , 1988, Diabetes.

[132]  B. Sobel,et al.  Regulation of the expression of type 1 plasminogen activator inhibitor in Hep G2 cells by epidermal growth factor. , 1988, The Journal of biological chemistry.

[133]  G. Hallmans,et al.  The effect of body build, diet and endocrine factors on the extrinsic fibrinolytic system in healthy young women. , 1988, Scandinavian journal of clinical and laboratory investigation.

[134]  A. Maseri,et al.  Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. , 1988, The American journal of cardiology.

[135]  S. Rapaport,et al.  Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[136]  C. Soria,et al.  Association between coagulation factors VII and X with triglyceride rich lipoproteins. , 1988, Journal of clinical pathology.

[137]  P. Sever,et al.  Diabetic hypertension--the importance of fibrinogen and blood viscosity. , 1988, Journal of human hypertension.

[138]  Y. Takada,et al.  Relationship between smoking and fibrinolytic system with special reference to t-PA and PA inhibitor. , 1988, Thrombosis research.

[139]  E. Kruithof,et al.  Diurnal Variation of the Fibrinolytic System , 1988, Thrombosis and Haemostasis.

[140]  M. L. Larsen,et al.  Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). , 1988, Thrombosis research.

[141]  L. Romics,et al.  Lipoprotein (a) and plasminogen are immunochemically related. , 1988, Biochimica et biophysica acta.

[142]  F. España,et al.  Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. , 1988, British heart journal.

[143]  Y. Vandekerckhove,et al.  Plasma tissue plasminogen activator levels in patients with coronary heart disease. , 1988, Thrombosis research.

[144]  M. Hultin,et al.  Factor VII activity state in coronary artery disease. , 1988, The Journal of laboratory and clinical medicine.

[145]  S. Rahimtoola,et al.  Impaired fibrinolysis in coronary artery disease. , 1988, American heart journal.

[146]  B. Sobel,et al.  Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications. , 1988, Circulation.

[147]  T. Meade,et al.  SMOKING AND PLASMA FIBRINOGEN , 1988, The Lancet.

[148]  J. Miletich,et al.  The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action , 1988 .

[149]  J. Auwerx,et al.  Tissue‐Type Plasminogen Activator Antigen and Plasminogen Activator Inhibitor in Diabetes Mellitus , 1988, Arteriosclerosis.

[150]  V. Nguyen.  Fibrinogen and risk of cardiovascular disease: Kannel WB, Wolf PA, Castelli WP, et al JAMA 258: 1183–1186 Sep 1987 , 1988 .

[151]  Y. Nemerson.  Tissue factor and hemostasis. , 1988, Blood.

[152]  P Smith,et al.  FACTOR VII-PHOSPHOLIPID COMPLEX IN MALE SURVIVIRS OF ACUTE MYCORDIAL INFARCTION , 2009, Thrombosis and Haemostasis.

[153]  J. Jespersen,et al.  On the usefulness of fibrinolysis variables in the characterization of a risk group for myocardial reinfarction. , 2009, Acta medica Scandinavica.

[154]  M. Bednarek,et al.  DETECTION OF FACTOR X ACTIVATION IN HUMANS , 1989, Thrombosis and Haemostasis.

[155]  S. Thompson,et al.  Sources of Variability in Coagulation Factor Assays , 1987, Thrombosis and Haemostasis.

[156]  T. Nilsson,et al.  The extrinsic fibrinolytic system in survivors of myocardial infarction. , 1987, Thrombosis research.

[157]  Fey Gh,et al.  Regulation of acute phase gene expression by inflammatory mediators. , 1987 .

[158]  E. Chen,et al.  cDNA sequence of human apolipoprotein(a) is homologous to plasminogen , 1987, Nature.

[159]  T. Meade,et al.  EFFECTS OF CHANGES IN SMOKING AND OTHER CHARACTERISTICS ON CLOTTING FACTORS AND THE RISK OF ISCHAEMIC HEART DISEASE , 1987, The Lancet.

[160]  M. Blombäck,et al.  GENETIC AND CULTURAL INHERITANCE OF PLASMA FIBRINOGEN CONCENTRATION , 1987, The Lancet.

[161]  J. Miletich,et al.  Absence of thrombosis in subjects with heterozygous protein C deficiency. , 1987, The New England journal of medicine.

[162]  B. Coller,et al.  Deficiency of Plasma Protein S, Protein C, or Antithrombin III and Arterial Thrombosis , 1987, Arteriosclerosis.

[163]  V. Fuster,et al.  Restenosis after arterial angioplasty: a hemorrheologic response to injury. , 1987, The American journal of cardiology.

[164]  M. Blombäck,et al.  PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION , 1987, The Lancet.

[165]  P. Vague,et al.  Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1. , 1987, Diabete & metabolisme.

[166]  S. Humphries,et al.  ROLE OF GENETIC VARIATION AT THE FIBRINOGEN LOCUS IN DETERMINATION OF PLASMA FIBRINOGEN CONCENTRATIONS , 1987, The Lancet.

[167]  M. Esnouf,et al.  Turnover of factor X and of prothrombin in rabbits fed on a standard or cholesterol-supplemented diet. , 1987, The Biochemical journal.

[168]  E. Briët,et al.  Hereditary protein S deficiency: clinical manifestations. , 1987, Annals of internal medicine.

[169]  J. T. ten Cate,et al.  Tissue plasminogen activator activity and inhibition in acute myocardial infarction and angiographically normal coronary arteries. , 1987, The American journal of cardiology.

[170]  J. Jespersen,et al.  A Selective Depression of Tissue Plasminogen Activator (t-PA) Activity in Euglobulins Characterises a Risk Group Among Survivors of Acute Myocardial Infarction , 1987, Thrombosis and Haemostasis.

[171]  T. Saldeen,et al.  Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. , 1987, Journal of the American College of Cardiology.

[172]  G. Stamatoyannopoulos,et al.  The molecular basis of blood diseases , 1987 .

[173]  T. Meade,et al.  Increased factor VII coagulant activity in the rabbit following diet-induced hypercholesterolaemia. Evidence for increased conversion of VII to alpha VIIa and higher flux within the coagulation pathway. , 1987, Atherosclerosis.

[174]  E. Smith,et al.  Soluble fibrin/fibrinogen related antigen in human intima in relation to atherogenesis , 1986 .

[175]  L Morgenstern,et al.  Coronary angioscopy in patients with unstable angina pectoris. , 1986, The New England journal of medicine.

[176]  S. Thompson,et al.  HAEMOSTATIC FUNCTION AND ISCHAEMIC HEART DISEASE: PRINCIPAL RESULTS OF THE NORTHWICK PARK HEART STUDY , 1986, The Lancet.

[177]  G. Lowe.  Blood rheology in arterial disease. , 1986, Clinical science.

[178]  W. H. Wilkinson,et al.  Association between dietary fat intake and plasma factor VII coagulant activity--a predictor of cardiovascular mortality. , 1986, Atherosclerosis.

[179]  M. Alessi,et al.  Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. , 1986, Metabolism: clinical and experimental.

[180]  G. Bondjers,et al.  Regional Accumulations of T Cells, Macrophages, and Smooth Muscle Cells in the Human Atherosclerotic Plaque , 1986, Arteriosclerosis.

[181]  M. Blombäck,et al.  Haemostatic function in myocardial infarction. , 1986, British heart journal.

[182]  B. Blombäck.  Fibrinogen to fibrin - an overview , 1985 .

[183]  M. Blombäck,et al.  Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. , 1985, The New England journal of medicine.

[184]  P. Mannucci,et al.  Fibrinolytic shut‐down after surgery: impairment of the balance between tissue‐type plasminogen activator and its specific inhibitor , 1985, European journal of clinical investigation.

[185]  M. C. Stone,et al.  Plasma fibrinogen--a major coronary risk factor. , 1985, The Journal of the Royal College of General Practitioners.

[186]  E. Braunwald,et al.  Circadian variation in the frequency of onset of acute myocardial infarction. , 1985, The New England journal of medicine.

[187]  C. Bulpitt,et al.  Fibrinogen: a possible link between social class and coronary heart disease. , 1985, British medical journal.

[188]  I. Hjermann,et al.  A novel form of factor VII in plasma from men at risk for cardiovascular disease , 1985, British journal of haematology.

[189]  M. Samama,et al.  FURTHER EVIDENCE THAT ACTIVATED FACTOR VII IS RELATED TO PLASMA LIPIDS , 1985, British journal of haematology.

[190]  C. Kluft,et al.  Effect of Chronic Smoking on Fibrinolysis , 1985, Arteriosclerosis.

[191]  F. Werf,et al.  Plasminogen activator inhibitor in the blood of patients with coronary artery disease. , 1985, British medical journal.

[192]  R. Mulroy.  General practitioner and long term care of patients with a spinal injury. , 1985, British medical journal.

[193]  H. Schulte,et al.  Epidemiological Study on Factor VII, Factor VIII and Fibrinogen in an Industrial Population: I. Baseline Data on the Relation to Age, Gender, Body-Weight, Smoking, Alcohol, Pill-Using, and Menopause , 1985, Thrombosis and Haemostasis.

[194]  S. Rapaport,et al.  Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component. , 1985, Blood.

[195]  S. Thompson,et al.  The effect of physiological levels of fibrinogen on platelet aggregation. , 1985, Thrombosis research.

[196]  M J Davies,et al.  Plaque fissuring--the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. , 1985, British heart journal.

[197]  S. Thompson,et al.  Epidemiological characteristics of platelet aggregability. , 1985, British medical journal.

[198]  V. V. van Hinsbergh,et al.  Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. , 1985, Blood.

[199]  J. Griffin,et al.  Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[200]  B. Wiman,et al.  Plasma fibrinolytic activity in patients undergoing major abdominal surgery. , 1985, Acta chirurgica Scandinavica.

[201]  P. Mannucci,et al.  Protein C Antigen Is Not an Acute Phase Reactant and Is often High in Ischemic Heart Disease and Diabetes , 1984, Thrombosis and Haemostasis.

[202]  R. Bertina,et al.  Protein C values in coronary artery disease. , 1984, British medical journal.

[203]  C. Kluft,et al.  Acute effect of smoking on fibrinolysis: increase in the activity level of circulating extrinsic (tissue‐type) plasminogen activator* , 1984, European journal of clinical investigation.

[204]  T. Nilsson,et al.  Defective fibrinolysis in survivors of myocardial infarction. , 1984, International Journal of Cardiology.

[205]  L. Wilhelmsen,et al.  Fibrinogen as a risk factor for stroke and myocardial infarction. , 1984, The New England journal of medicine.

[206]  M J Davies,et al.  Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. , 1984, The New England journal of medicine.

[207]  H. Prydz,et al.  The coagulation factor VII in pregnancy , 1984, British journal of haematology.

[208]  R. Doolittle.  Fibrinogen and fibrin. , 1984, Annual review of biochemistry.

[209]  E. Raftery,et al.  Haemostatic Variables and the Outcome of Myocardial Infarction , 1983, Thrombosis and Haemostasis.

[210]  S. Yu,et al.  Intracellular assembly of human fibrinogen. , 1983, The Journal of biological chemistry.

[211]  E. Falk.  Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. , 1983, British heart journal.

[212]  L. Goodnough,et al.  Thrombosis or Myocardial Infarction in Congenital Clotting Factor Abnormalities and Chronic Thrombocytopenias: A Report of 21 Patients and a Review of 50 Previously Reported Cases , 1983, Medicine.

[213]  D. Berman,et al.  Nonsurgical reperfusion in evolving myocardial infarction. , 1983, Journal of the American College of Cardiology.

[214]  T. Meade,et al.  HYPERTRIGLYCERIDAEMIA AND HYPERCOAGULABILITY , 1983, The Lancet.

[215]  B. Blombäck,et al.  Calcium and fibrin gel structure. , 1983, Thrombosis research.

[216]  D. Ritchie,et al.  Regulation of fibrinogen synthesis by plasmin-derived fragments of fibrinogen and fibrin: an indirect feedback pathway. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[217]  B. Blombäck,et al.  Fibrin gel structure and clotting time. , 1982, Thrombosis research.

[218]  D. Steinberg,et al.  Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[219]  Elspeth B. Smith,et al.  HAEMOSTATIC FACTORS IN HUMAN AORTIC INTIMA , 1981, The Lancet.

[220]  J. Kramer,et al.  Progression of Coronary Atherosclerosis , 1981, Circulation.

[221]  M S Golden,et al.  Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. , 1980, The New England journal of medicine.

[222]  T. Meade,et al.  Effect of treatment of hyperlipidaemia on haemostatic variables. , 1980, British medical journal.

[223]  S. Thompson,et al.  HÆMOSTATIC FUNCTION AND CARDIOVASCULAR DEATH: EARLY RESULTS OF A PROSPECTIVE STUDY , 1980, The Lancet.

[224]  I Hutton,et al.  Relation between extent of coronary artery disease and blood viscosity. , 1980, British medical journal.

[225]  Elspeth B. Smith,et al.  ROLE OF ENDOTHELIUM IN SEQUESTRATION OF LIPOPROTEIN AND FIBRINOGEN IN AORTIC LESIONS, THROMBI, AND GRAFT PSEUDO-INTIMAS , 1979, The Lancet.

[226]  H. Keen,et al.  Haemostatic variables associated with diabetes and its complications. , 1979, British medical journal.

[227]  K. Pyörälä.  Relationship of Glucose Tolerance and Plasma Insulin to the Incidence of Coronary Heart Disease: Results from Two Population Studies in Finland , 1979, Diabetes Care.

[228]  T. Welborn,et al.  Coronary Heart Disease Incidence and Cardiovascular Mortality in Busselton with Reference to Glucose and Insulin Concentrations , 1979, Diabetes Care.

[229]  A. P. Haines,et al.  Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations. , 1979, British medical journal.

[230]  W. O'Fallon,et al.  Increased von Willebrand factor in diabetes mellitus. , 1979, Metabolism: clinical and experimental.

[231]  J. Erikssen,et al.  Plasma Antithrombin III and Factor VIII Antigen in Relation to Angiographic Findings, Angina and Blood Groups in Middle-Aged Men , 1977, Thrombosis and Haemostasis.

[232]  B. Osterud,et al.  Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[233]  T. Lawrie,et al.  Disordered "fibrinolytic potential" in coronary heart disease. , 1977, Thrombosis research.

[234]  M. Gertler,et al.  Alteration of Plasma Antithrombin III Levels in Ischemic Heart Disease , 1976, Thrombosis and Haemostasis.

[235]  M. Etherington,et al.  Blood Changes in Atherosclerosis and Long After Myocardial Infarction and Venous Thrombosis , 1975, Thrombosis and Haemostasis.

[236]  C. Warlow,et al.  Fibrinolytic capacity of arm and leg veins after femoral shaft fracture and acute myocardial infarction. , 1975, British medical journal.

[237]  Oxon Dm.  Obituary. Rupert Samuel Bruce Pearson. , 1974 .

[238]  Maddocks Ac.  Letter: Sterilisation of cardiac bioptome. , 1974 .

[239]  V. Kumar,et al.  Antithrombin III Deficiency in Maturity Onset Diabetes Mellitus and Atherosclerosis , 1974, Thrombosis and Haemostasis.

[240]  B. Williams,et al.  AETIOLOGY OF STRIAE GRAVIDARUM , 1974 .

[241]  K. Porter.  Letter: Nitrous-oxide asphyxia. , 1974, Lancet.

[242]  D. Jackson,et al.  Fibrinolytic activity and coronary-artery disease. , 1968, Lancet.

[243]  J. B. Duguid.  Thrombosis as a factor in the pathogenesis of coronary atherosclerosis. , 1946, The Journal of pathology and bacteriology.